Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2016

Open Access 01-12-2016 | Review

Clinical significance of microRNAs in chronic and acute human leukemia

Authors: Chien-Hung Yeh, Ramona Moles, Christophe Nicot

Published in: Molecular Cancer | Issue 1/2016

Login to get access

Abstract

Small non-coding microRNAs (miRNAs) are epigenetic regulators that target specific cellular mRNA to modulate gene expression patterns and cellular signaling pathways. miRNAs are involved in a wide range of biological processes and are frequently deregulated in human cancers. Numerous miRNAs promote tumorigenesis and cancer progression by enhancing tumor growth, angiogenesis, invasion and immune evasion, while others have tumor suppressive effects (Hayes, et al., Trends Mol Med 20(8): 460–9, 2014; Stahlhut and Slack, Genome Med 5 (12): 111, 2013). The expression profile of cancer miRNAs can be used to predict patient prognosis and clinical response to treatment (Bouchie, Nat Biotechnol 31(7): 577, 2013). The majority of miRNAs are intracellular localized, however circulating miRNAs have been detected in various body fluids and represent new biomarkers of solid and hematologic cancers (Fabris and Calin, Mol Oncol 10(3):503–8, 2016; Allegra, et al., Int J Oncol 41(6): 1897–912, 2012). This review describes the clinical relevance of miRNAs, lncRNAs and snoRNAs in the diagnosis, prognosis and treatment response in patients with chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and acute adult T-cell leukemia (ATL).
Literature
1.
2.
Calin GA et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9.PubMedPubMedCentralCrossRef
3.
Sampath D et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 2012;119(5):1162–72.PubMedPubMedCentralCrossRef
4.
5.
6.
Dohner H et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.PubMedCrossRef
7.
Marcucci G et al. MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. Best Pract Res Clin Haematol. 2009;22(2):239–48.PubMedCrossRef
8.
Auer RL, Riaz S, Cotter FE. The 13q and 11q B-cell chronic lymphocytic leukaemia-associated regions derive from a common ancestral region in the zebrafish. Br J Haematol. 2007;137(5):443–53.PubMedCrossRef
9.
Merkel O et al. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle. 2010;9(14):2764–8.PubMedCrossRef
10.
Zenz T et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589–97.PubMedCrossRef
11.
Zauli G et al. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res. 2011;17(9):2712–24.PubMedCrossRef
12.
Xiao C et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405–14.PubMedPubMedCentralCrossRef
13.
Mraz M et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014;124(1):84–95.PubMedPubMedCentralCrossRef
14.
Rozovski U et al. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 2013;12:50.PubMedPubMedCentralCrossRef
15.
Ferrajoli A et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122(11):1891–9.PubMedPubMedCentralCrossRef
16.
Guinn D et al. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with ibrutinib. Leukemia. 2015;29(5):1210–3.PubMedPubMedCentralCrossRef
17.
Cui B et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546–54.PubMedPubMedCentralCrossRef
18.
19.
20.
Puente XS, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519–24.
21.
Baer C et al. Epigenetic silencing of miR-708 enhances NF-kappaB signaling in chronic lymphocytic leukemia. Int J Cancer. 2015;137(6):1352–61.PubMedCrossRef
22.
Mraz M et al. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012;119(9):2110–3.PubMedCrossRef
23.
Rossi S et al. MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010;116(6):945–52.PubMedCrossRef
24.
25.
Moussay E et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer. 2010;9:115.PubMedPubMedCentralCrossRef
26.
Zenz T et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–9.PubMedCrossRef
27.
Dufour A et al. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood. 2013;121(18):3650–7.PubMedCrossRef
28.
Blume CJ et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 2015;29(10):2015–23.PubMedCrossRef
29.
Tavolaro S et al. Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. Genes Chromosomes Cancer. 2015;54(4):222–34.PubMedCrossRef
30.
Stamatopoulos B et al. MicroRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113(21):5237–45.PubMedCrossRef
31.
Zhou K et al. MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(6):1155–61.PubMedCrossRef
32.
Zhou K et al. miR-29c down-regulation is associated with disease aggressiveness and poor survival in chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(7):1544–50.PubMedCrossRef
33.
34.
Stamatopoulos B et al. Opposite prognostic significance of cellular and serum circulating MicroRNA-150 in patients with chronic lymphocytic leukemia. Mol Med. 2015;21:123–33.PubMedPubMedCentralCrossRef
35.
Lugo TG et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079–82.PubMedCrossRef
36.
Gordon JE, Wong JJ, Rasko JE. MicroRNAs in myeloid malignancies. Br J Haematol. 2013;162(2):162–76.PubMedCrossRef
37.
Venturini L et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399–405.PubMedCrossRef
38.
Eiring AM, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652-65.
39.
40.
Lopotova T et al. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res. 2011;35(7):974–7.PubMedCrossRef
41.
Bueno MJ et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13(6):496–506.PubMedCrossRef
42.
Agirre X et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830–40.PubMedCrossRef
43.
44.
Machova Polakova, K., et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10:41.
45.
46.
San Jose-Eneriz E, et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69.
47.
Ferreira AF, et al. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Blood Cells Mol Dis. 2014;53(1–2):47–55.PubMedCrossRef
48.
49.
Hershkovitz-Rokah O, et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 2015;360(2):245–56.PubMedCrossRef
50.
Hershkovitz-Rokah O, et al. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 2015;356(2 Pt B):597–605.PubMedCrossRef
51.
Xishan Z, et al. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia. Cancer Gene Ther. 2014;21(9):397–404.PubMedCrossRef
52.
53.
Joshi D, et al. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene. 2014;542(2):109–12.PubMedCrossRef
54.
Nishioka C, et al. Downregulation of miR-217 correlates with resistance of Ph (+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Sci. 2014;105(3):297–307.PubMedPubMedCentralCrossRef
55.
Zhu X, et al. Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. Cancer Gene Ther. 2015;22(12):573–80.PubMedCrossRef
56.
Ohyashiki JH, et al. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. Drug Des Devel Ther. 2014;8:1151–9.PubMedPubMedCentralCrossRef
57.
Luan C, Yang Z, Chen B. The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. Onco Targets Ther. 2015;8:2903–14.PubMedPubMedCentral
58.
Fulci V, et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer. 2009;48(12):1069–82.PubMedCrossRef
59.
Mavrakis KJ, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). (1546–1718 (Electronic)).
60.
Mavrakis KJ, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 2011;43(7):673–8.
61.
Nemes K, et al. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathol Oncol Res. 2015;21(3):597–604.PubMedCrossRef
62.
Gutierrez-Camino A, et al. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility. Pediatr Res. 2014;75(6):767–73.PubMedCrossRef
63.
de Leeuw DC, et al. MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. Clin Cancer Res. 2013;19(8):2187–96.
64.
Mi S, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104(50):19971–6.PubMedPubMedCentralCrossRef
65.
66.
Agirre X, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69(10):4443–53.PubMedCrossRef
67.
Schotte D, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 2011;96(5):703–11.PubMedPubMedCentralCrossRef
68.
Zhang H, et al. Genome-wide analysis of small RNA and novel MicroRNA discovery in human acute lymphoblastic leukemia based on extensive sequencing approach. PLoS One. 2009;4(9), e6849.PubMedPubMedCentralCrossRef
69.
Sugita F, et al. Overexpression of MIR9 indicates poor prognosis in acute lymphoblastic leukemia. Leuk Lymphoma. 2014;55(1):78–86.PubMedCrossRef
70.
Ohyashiki JH, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 2010;3:347.PubMedPubMedCentralCrossRef
71.
Yan J, et al. Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia. Br J Haematol. 2013;163(1):93–103.PubMedCrossRef
72.
Mei Y, et al. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci. 2014;105(4):463–72.PubMedPubMedCentralCrossRef
73.
Lv M, et al. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways. Leukemia. 2012;26(4):769–77.PubMedCrossRef
74.
Avigad S, et al. miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2016;55(4):328–39.PubMedCrossRef
75.
76.
Zhang H, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009;4(11):e7826.PubMedPubMedCentralCrossRef
77.
Han BW, et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet. 2011;20(24):4903–15.PubMedPubMedCentralCrossRef
78.
Rainer J, et al. Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia. 2009;23(4):746–52.PubMedCrossRef
79.
Kaddar T, et al. Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. Leuk Res. 2009;33(9):1217–23.PubMedCrossRef
80.
Han J, Chen Q. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Int J Clin Exp Pathol. 2015;8(10):12698–707.
81.
Schotte D, et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(2):313–22.PubMedCrossRef
82.
de Oliveira JC, et al. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res. 2012;36(3):293–8.PubMedCrossRef
83.
Kotani A, et al. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood. 2009;114(19):4169–78.PubMedPubMedCentralCrossRef
84.
Lu J, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.
85.
Xia ZB, et al. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A. 2005;102(39):14028–33.
86.
87.
88.
89.
Sandhu R, Rivenbark AG, Coleman WB. Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines. Int J Oncol. 2012;41(2):721–32.PubMedPubMedCentral
90.
91.
Zhang H, et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer. 2011;10:108.PubMedPubMedCentralCrossRef
92.
93.
Taganov KD, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(33):12481–6.PubMedPubMedCentralCrossRef
94.
Chen CZ, et al. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83–6.PubMedCrossRef
95.
Tam W, Dahlberg JE. miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer. 2006;45(2):211–2.PubMedCrossRef
96.
97.
98.
Palma Ca Fau - Al Sheikha D, et al. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia. Mol Cancer. 2014;13:79.
99.
100.
Jinlong S, et al. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. PLoS One. 2015;10(2):e0118099.PubMedPubMedCentralCrossRef
101.
Marcucci G, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919–28.PubMedCrossRef
102.
Schwind S, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(36):5257–64.PubMedPubMedCentralCrossRef
103.
Li Z, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012;119(10):2314–24.PubMedPubMedCentralCrossRef
104.
Lu F, et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 2014;45(1):383–92.PubMed
105.
Xiang L, et al. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Ann Hematol. 2013;92(8):1063–9.PubMedCrossRef
106.
Diaz-Beya M, et al. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia. 2014;28(4):804–12.PubMedCrossRef
107.
Li Z, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008;105(40):15535–40.PubMedPubMedCentralCrossRef
108.
109.
Zhu C, et al. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem. 2013;46(1–2):49–53.PubMedCrossRef
110.
Xiong Y, et al. MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol. 2011;153(6):753–7.PubMedPubMedCentralCrossRef
111.
Dahlhaus M, et al. Expression and prognostic significance of hsa-miR-142-3p in acute leukemias. Neoplasma. 2013;60(4):432–8.PubMedCrossRef
112.
Rucker FG, et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia. 2013;27(2):353–61.PubMedCrossRef
113.
114.
Butrym A, et al. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients. J Exp Clin Cancer Res. 2015;34:68.PubMedPubMedCentralCrossRef
115.
Garzon R, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008;105(10):3945–50.
116.
Sun SM, et al. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 2013;27(1):100–6.PubMedCrossRef
117.
Chuang MK, et al. A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. Leukemia. 2015;29(5):1051–9.PubMedCrossRef
118.
Gentner B, et al. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol. 2015;43(10):858–68. e7.PubMedPubMedCentralCrossRef
119.
Zoni E, Kruithof-de Julio M, G. van der Pluijm. miR-25, integrin and cancer invasiveness. Oncoscience. 2015;2(8):663–4.
120.
Jia CY, et al. MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One. 2011;6(11):e27008. E-publication.
121.
Qian J, et al. Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia. Leuk Res. 2013;37(7):765–8.PubMedCrossRef
122.
Xu LH, et al. Overexpressed miR-155 is associated with initial presentation and poor outcome in chinese pediatric acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2015;19(24):4841–50.PubMed
123.
de Leeuw DC, et al. Attenuation of microRNA-126 expression that drives CD34 + 38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res. 2014;74(7):2094–105.PubMedCrossRef
124.
Shibayama Y, et al. Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep. 2015;33(5):2176–82.PubMedPubMedCentral
125.
126.
Chen XX, et al. Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem. 2014;47(1–2):63–6.PubMedCrossRef
127.
128.
Marcucci G, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31(17):2086–93.PubMedPubMedCentralCrossRef
129.
Diaz-Beya M, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015;5, e352.PubMedPubMedCentralCrossRef
130.
Eisfeld AK, et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 2012;120(2):249–58.PubMedPubMedCentralCrossRef
131.
Li Y, et al. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res. 2013;37(12):1642–7.PubMedCrossRef
132.
Blum W, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16):7473–8.PubMedPubMedCentralCrossRef
133.
Swellam M and El-Khazragy N. Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia. Tumour Biol, 2016. pp 1–6.
134.
Kozloski GAA-Ohoo, et al. MiR-181a negatively regulates NF-kappaB signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis. LID - blood-2015-11-680462 [pii]. Blood. 2016. Epub ahead of print.
135.
Bresin A, et al. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Emicro-TCL1 mouse model. Oncotarget. 2015;6(23):19807–18.
136.
Yin JJ, Liang B, and Zhan XR. MicroRNA-204 inhibits cell proliferation in T-cell acute lymphoblastic leukemia by down-regulating SOX4. Int J Clin Exp Pathol. 2015;8(8):9189–95.
137.
Butrym A, et al. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med. 2015;9(5):453–60.PubMedCrossRef
138.
Chang RM, et al. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60(4):1251–63.
139.
Lin X, et al. High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia. Clin Transl Oncol. 2015;17(5):358–64.PubMedCrossRef
140.
Yingchun L, et al. Bone marrow MicroRNA-335 level predicts the chemotherapy response and prognosis of adult acute myeloid leukemia. Medicine (Baltimore). 2015;94(33), e0986.CrossRef
141.
Lin X, et al. High serum microRNA-335 level predicts aggressive tumor rogression and unfavorable prognosis in pediatric acute myeloid leukemia. (1699–3055 (Electronic)).
142.
Havelange V, et al. Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood. 2014;123(15):2412–5.
143.
144.
Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79(6):2031–5.PubMedPubMedCentralCrossRef
145.
Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol. 2005;78(3):232–9.PubMedCrossRef
146.
Bellon M, et al. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood. 2009;113(20):4914–7.PubMedPubMedCentralCrossRef
147.
Pichler K, Schneider G, and Grassmann R. MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology, 2008;5:100.
148.
Yamagishi M, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell. 2012;21(1):121–35.PubMedCrossRef
149.
Bellon M, Lu L, and Nicot C. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. Blood, 2016. Epub ahead of print.
150.
Gazon H, et al. Impaired expression of DICER and some microRNAs in HBZ expressing cells from acute adult T-cell leukemia patients. Oncotarget, 2016. Epub ahead of print.
151.
Tomita M, Tanaka Y, Mori N. MicroRNA miR-146a is induced by HTLV-1 tax and increases the growth of HTLV-1-infected T-cells. Int J Cancer. 2012;130(10):2300–9.PubMedCrossRef
152.
Tomita, M. Important Roles of Cellular MicroRNA miR-155 in Leukemogenesis by Human T-Cell Leukemia Virus Type 1 Infection. ISRN Microbiol. 2012;2012:978607.
153.
Moles R, Bellon M, Nicot C. STAT1: a novel target of miR-150 and miR-223 is involved in the proliferation of HTLV-I-transformed and ATL cells. Neoplasia. 2015;17(5):449–62.PubMedPubMedCentralCrossRef
154.
155.
Ishihara K et al. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol. 2012;36(6):560–5.PubMedCrossRef
156.
Nicot C et al. Tax oncoprotein trans-represses endogenous B-myb promoter activity in human T cells. AIDS Res Hum Retroviruses. 2000;16(16):1629–32.PubMedCrossRef
157.
Nicot C et al. HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300. Oncogene. 2000;19(17):2155–64.PubMedCrossRef
158.
Xia H, et al. Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia/lymphoma. Hum Pathol. 2014;45(6):1192–8.PubMedCrossRef
159.
160.
161.
162.
Yeh YY, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015;125(21):3297–305.PubMedPubMedCentralCrossRef
163.
164.
165.
166.
Wang Z, et al. Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia. Mol Cell Biochem. 2013;383(1–2):59–65.PubMedCrossRef
167.
Luna-Aguirre CM, et al. Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia. Cancer Biomark. 2015;15(3):299–310.PubMedCrossRef
168.
169.
Chaligne R, Heard E. X-chromosome inactivation in development and cancer. FEBS Lett. 2014;588(15):2514–22.PubMedCrossRef
170.
171.
Wang Y, et al. LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Sci Rep. 2015;5:13749.PubMedPubMedCentralCrossRef
172.
Guo G, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Oncogene. 2015;34(14):1768–79.PubMedCrossRef
173.
Guo G, et al. High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett. 2014;588(9):1780–6.PubMedCrossRef
174.
Tay Y, et al. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep. 2014;8(3):714–22.PubMedPubMedCentralCrossRef
175.
Kallen AN, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52(1):101–12.PubMedCrossRef
176.
Sun J, et al. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res. 2014;42(15):9588–601.PubMedPubMedCentralCrossRef
177.
178.
179.
Valleron W, et al. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia. 2012;26(9):2052–60.PubMedCrossRef
180.
181.
Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.PubMedCrossRef
182.
183.
Fabris L, Calin GA. Circulating free xeno-microRNAs—the new kids on the block. Mol Oncol. 2016;10(3):503–8.PubMedCrossRef
184.
Allegra A, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897–912.PubMed
185.
Metadata
Title
Clinical significance of microRNAs in chronic and acute human leukemia
Authors
Chien-Hung Yeh
Ramona Moles
Christophe Nicot
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-016-0518-2

Other articles of this Issue 1/2016

Molecular Cancer 1/2016 Go to the issue

Research

Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway

Research

MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression

Research

Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells – evidence for a role in hepatocellular carcinoma growth in vivo

Research

ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models

Review

Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis

Research

miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits